Edison Investment Research - Symbio Pharmaceuticals (4582) SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales

Report

Edison Investment Research

Sean Conroy

SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales

SymBio reported Q121 sales of ¥1.42bn of its drug Treakisym (bendamustine) for hematologic malignancies. This is the first quarter in which the product is being sold by SymBio directly, and it marks a substantial increase over prior sales trends. Sales have more than doubled since Q420 (¥0.6bn). Part of what is driving this is the early 2021 launch of the company’s ready-to-dilute (RTD) formulation. Moreover, SymBio recently expanded the indications approved for the drug to include diffuse large B-cell lymphoma (DLBCL), which may also drive future sales.

27/05/2021 5 EN

Underlying

Symbio Pharmaceuticals

Symbio Pharmaceuticals is a specialty biopharmaceutical company based in Japan. Co. specializes in the development and commercialization of drug candidates in oncology, hematology and autoimmunity areas. Co. has built pipelines (a group of newly developed drugs) with several pharmaceuticals, as well as, newly developed drugs in these disease areas. Co.'s product pipeline includes SyB L-0501(treatment of non-Hodgkin's lymphoma and mantle cell lymphoma); SyB L-1101/SyB C-1101, a multi-kinase inhibitor for the treatment of refractory/relapse myelodysplastic syndromes and solid tumor indications; and SyB D-0701, an antiemetic transdermal patch.

See profile

JP3383050006 Japan

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

SymBio Pharmaceuticals - Termination of coverage

Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ), CiiTECH and Marshall Motor Holdings (MMH). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

April 29, 2022 April 29, 2022 1 EN

Edison Investment Research

SymBio Pharmaceuticals - Treakisym approved for DLBCL

SymBio announced on 23 March 2021 that it has received marketing approval for Treakisym (bendamustine) for diffuse large B-cell lymphoma (DLBCL). The drug has been approved for relapsed and refractory disease in two combinations: with rituximab and polatuzumab vedotin or with rituximab alone. We expect this approval to approximately double the addressable market for the drug in Japan.

March 30, 2021 March 30, 2021 5 EN

Datatec - FY24 underlying EPS more than doubles y-o-y

In a second more detailed trading update for FY24, Datatec confirmed revenue growth of 6% to $5.46bn, with Westcon International delivering excellent performance, Logicalis International having a strong H2 and Logicalis Latin America affected by difficult market conditions in Argentina and Brazil. The company also provided provisional EPS data, with reported EPS likely to come in ahead of our forecast and underlying EPS just below our forecast. We maintain our forecasts pending FY24 results on or around 27 May.

17h / 4m 17h / 4m 1 EN

Alison Turner

Alison Turner

Pan American Silver - La Arena divestment

Pan American Silver (PAAS) has announced a sale of the La Arena and La Arena II projects to Zijin Mining for US$245m in cash, US$50m in a contingent payment and a 1.5% NSR gold royalty. La Arena II is a copper and gold sulphide deposit that sits underneath the currently producing La Arena gold project. We view the transaction as positive for PAAS, given La Arena’s very short mine life, significant capex required to bring La Arena II into production and the fact that copper is not PAAS’s core commodity.

17h / 50m 17h / 50m 1 EN

Richard Williamson

Richard Williamson

SenSen Networks - Time to scale

SenSen’s Q324 results reflect the move to a lower cost base that provides a platform for future profitability. Minor delays to the National Heavy Vehicle Regulator (NHVR) contract affected Q3 but should not affect FY24 as most of the deployment is now complete. North American Smart Cities growth is gaining traction via partnerships, underpinning Q424 momentum alongside strong fuel theft solution uptake. Restructuring to drive a return to sustainable free cash flow is mostly complete but resulted in one-off costs. We revise down our FY24 forecasts assuming similar Q4 growth from a lower Q3 base...

21h / 4m 21h / 4m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales

SymBio Pharmaceuticals - Termination of coverage

SymBio Pharmaceuticals - Treakisym approved for DLBCL

Datatec - FY24 underlying EPS more than doubles y-o-y

Pan American Silver - La Arena divestment

SenSen Networks - Time to scale

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe